Rosenthal Mark A, Kavar Bhadu, Uren Shannon, Kaye Andrew H
Centre for Developmental Cancer Therapeutics, Parkville, Victoria, Australia.
J Clin Neurosci. 2003 Jul;10(4):425-7. doi: 10.1016/s0967-5868(03)00062-6.
Current treatment strategies for high-grade gliomas are inadequate with high rates of disease recurrence and poor overall survival. Photodynamic therapy has been extensively investigated for a variety of tumours including high-grade gliomas. We have previously described a novel boronated porphyrin (BOPP) which has highly selective uptake by tumour cells. A Phase I study documented that BOPP at a dose of 4mg/kg was well tolerated. We report here the survival data arising from this Phase I study. Overall 28 patients (pts) with high-grade gliomas were treated with BOPP photodynamic therapy with a median overall survival (OS) of 14 months (2-48+ months). Sixteen pts had glioblastoma multiforme (GBM) with a median OS of 8 months (2-38+). Of 9 pts with recurrent GBM, the median OS was 11 months (3-38+), with 56% surviving at least 12 months. In conclusion, BOPP photodynamic therapy was associated with encouraging survival particularly in the recurrent GBM setting.
目前针对高级别胶质瘤的治疗策略并不充分，疾病复发率高且总体生存率低。光动力疗法已针对包括高级别胶质瘤在内的多种肿瘤进行了广泛研究。我们之前描述了一种新型硼化卟啉（BOPP），它能被肿瘤细胞高度选择性摄取。一项I期研究表明，4mg/kg剂量的BOPP耐受性良好。我们在此报告这项I期研究的生存数据。总体而言，28例高级别胶质瘤患者接受了BOPP光动力治疗，中位总生存期（OS）为14个月（2 - 48 +个月）。16例患者患有多形性胶质母细胞瘤（GBM），中位OS为8个月（2 - 38 +）。在9例复发性GBM患者中，中位OS为11个月（3 - 38 +），56%的患者存活至少12个月。总之，BOPP光动力疗法的生存情况令人鼓舞，尤其是在复发性GBM患者中。
